References
Kapoor NS, Curcio LD, Blakemore CA, et al. Multigene panel testing detects equal rates of pathogenic BRCA1/2 mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol. 2015;22:3282–8.
Kleiblova P, Stolarova L, Krizova K, et al. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int J Cancer. 2019;145:1782–97.
Kuusisto, Bebel A, Vihinen M, et al. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res. 2011;13:R20.
Nizic-Kos T, Krajc M, Blatnik A, et al. Bilateral disease common among Slovenian CHEK2 positive breast cancer patients. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09178-y.
Akdeniz D, Schmidt MK, Seynaeve CM, et al. Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast. 2019;44:1–14.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Tea Nizic-Kos and Nikola Besic declare they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nizic-Kos, T., Besic, N. ASO Author Reflections: Contralateral Prophylactic Mastectomy in Breast Cancer Patients with CHEK2 Gene Mutations. Ann Surg Oncol 28, 2571–2572 (2021). https://doi.org/10.1245/s10434-020-09196-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09196-w